CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 41 enrolled
Drug / intervention
Fluvastatindrug
Likely dose
Fluvastatin 40 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00674297
NCT00674297Phase 2Completed
CompareCT.gov

Effects of Fluvastatin on Proinflammatory and Prothrombotic Markers in Antiphospholipid Syndrome Patients

Hospital for Special Surgery, New York·interventional·Posted May 7, 2008·Updated May 1, 2018

In Brief

A Phase 2 clinical trial evaluating Fluvastatin for Antiphospholipid Syndrome. Completed, enrolled 41 participants across 2 sites.

Detailed Summary

The purpose of this study is to determine whether a drug named Fluvastatin is beneficial and safe in reducing the risk of cardiovascular disease and blood clots in patients with antiphospholipid antibodies or Antiphospholipid Syndrome (APS).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAntiphospholipid Syndrome
CountriesUnited States
CollaboratorsUniversity of Texas

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 7, 2008
Enrollment StartMay 1, 2008
Primary CompletionJul 1, 2011
Study CompletionFeb 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 18.2 years ago

Interventions

Fluvastatindrug

Fluvastatin 40 mg daily for 3 months